Market Cap | ₹15,432Cr |
ROE | 24.79% |
P/E Ratio(TTM) | 9.09 |
EPS(TTM) | 94.78 |
P/B Ratio | 2.03 |
Dividend Yield | 0.70% |
Industry P/E | 34.34 |
Book Value | 424.71 |
Debt to Equity | 0.04 |
Face Value | 2 |
Parent Organisation | Natco Pharma Limited |
Managing Director | Shri. V. Nannapaneni |
NSE Symbol | NATCOPHARM |
FUND NAME | AUM(%) |
---|---|
Sundaram Small Cap Fund Direct Growth | 1.58% |
Tata Small Cap Fund Direct Growth | 0.45% |
Motilal Oswal Nifty 500 Index Fund Direct Growth | 0.04% |
COMPANY | 52 WEEK | MARKET PRICE | P/E Ratio | |
---|---|---|---|---|
Cohance Lifesciences | NA (0.00%) | 100.61 | ||
JB Chemicals & Pharmaceuticals | NA (0.00%) | 39.39 | ||
Emcure Pharmaceuticals | NA (0.00%) | 35.44 | ||
Wockhardt | NA (0.00%) | -188.59 |